GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Net Income Including Noncontrolling Interests

Roquefort Therapeutics (LSE:ROQ) Net Income Including Noncontrolling Interests : £-1.74 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Roquefort Therapeutics's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was £-0.96 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was £-1.74 Mil.

Roquefort Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Roquefort Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Net Income Including Noncontrolling Interests Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
- -1.62 -1.75

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests -0.30 -0.76 -0.85 -0.78 -0.96

Roquefort Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roquefort Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
AQSE:PBX LSE:BSFA LSE:BVX LSE:IMM LSE:OCTP LSE:CIZ LSE:IXI LSE:APTA LSE:ONC LSE:VAL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ROQAF:USA
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Website
https://www.roquefortplc.com
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines